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Abstract 
Objective: To evaluate the effect of laser irradiation at different wavelengths on the expression of selected 
growth factors and inflammatory mediators at particular stages of the wound healing process.  
Methods: Sixty-seven patients were recruited, treated, and analyzed (group A – 940 nm: 17 patients; group B 
– 808 nm: 18 patients; group C – 658 nm: 16 patients; group D – sham therapy: 17 patients). Patients received 
a basic treatment, including repositioning and mobilization, air pressure mattress and bed support surfaces, 
wound cleansing and drug therapy. Additionally, patients received laser therapy once a day, 5 times a week for 
1 month in use of a semiconductor lasers (GaAlAs) which emitted a continuous radiation emission at separate 
wavelengths of 940 nm (group A), 808 nm (group B) and 658 nm (group C). In group D (sham therapy), laser 
therapy was applied in the same manner, but the device was off during each session (only the applicator was 
switched on to scan pressure ulcers using none coherent red visible light).  
Results: The positive changes in the measured serum (IL-2, IL-6 and TNF-α) and wound tissue (TNF-α, VEGF 
and TGFβ1) parameters appeared to be connected only with the wavelength of 658 nm. The significant change 
in pro-inflammatory mediator levels [interleukin 2 (IL-2) with p=0.008 and interleukin 6 (IL-6) with p=0.016] 
was noticed after two weeks of laser therapy. In the other groups, the inflammation was also reduced, but the 
process was not as marked as in group C. Similarly, in the case of tumor necrosis factor (TNF-α) concentration, 
where after two weeks of treatment with irradiation at a wavelength of 658 nm, a rapid suppression was 
observed (p=0.001), whereas in the other groups, these results were much slower and not as obvious. 
Interestingly, again in the case of group C, the change in TNF-α concentration in wound tissue was most 
intensive (≈75% reduction), whereas the changes in other groups were not as obvious (≈50% reduction). After 
irradiation (658 nm), the VEGF expression increased significantly within the first two weeks, and then it 
decreased and maintained a stable level. In contrast, the TGFβ1 activity remained level, but always higher in 
comparison to other groups 
Conclusions: The effective healing of pressure ulcers is connected with laser irradiation at a wavelength of 
658 nm. We believe that this effect is related to the inhibition of inflammatory processes in the wound and 
stimulation of angiogenesis and fibroblast proliferation at this specific radiation (based both on concentration of 
interleukins and TNF-α serum level and VEGF, TGFβ1, TNF-α activities in wound biopsies). Laser therapy at 
wavelengths of 940 and 808 nm does not significantly affect the above-mentioned repair processes, which 
explains its low effectiveness in the treatment of pressure ulcers. 










The management of pressure ulcers is an 
extremely important clinical, social and economic 
problem [1, 2, 3]. It is upsetting that despite the 
enormous technological advances in medicine that 
have taken place over the last decades, there is still 
unsatisfactory effective, affordable, and versatile 
method of treatment for every patient with pressure 
ulcers (without many contraindications and 
limitations). Therefore, researchers are more inclined 
to seek new and unconventional methods, sometimes 
also in the field of physical therapy [4, 5, 6, 7, 8]. 
In recent years, the interest in the application of 
laser therapy in supporting chronic wound healing 
has increased [9, 10, 11]. However, the effectiveness 
and usefulness of this method has not been 
unequivocally confirmed so far. According to the 
latest (the next edition is scheduled for 2019) global 
consensus of three scientific societies dealing with the 
subject of treatment of pressure ulcers (the European 
and US National Pressure Ulcer Advisory Panels – 
EPUAP and NPUAP, along with the Pan Pacific 
Pressure Injury Alliance – PPPIA) entitled "Prevention 
and Treatment of Pressure Ulcers: Clinical Practice 
Guideline" [12], recommendations for the use of laser 
radiation are based only on vague presumptions and 
ambiguous conclusions arising from case reports (case 
studies or methodologically weak pilot clinical trials), 
comments and expert opinions. This is the reason why 
at this stage, recommendations for laser therapy as a 
treatment in pressure ulcers are on the lowest level of 
evidence, according to the Evidence-Based Medicine 
(EBM). 
In 2013, our team published the results of 
randomized clinical trial [13], which evaluated the 
efficacy of laser therapy at different wavelengths to 
treat pressure ulcers. Seventy-two patients with 
pressure ulcers were allocated to one of four 
comparison groups, in a single blind trial method 
with laser therapy at different wavelengths: (group 1) 
940 nm; (group 2), 808 nm; (group 3), 658 nm; and 
(group 4), sham laser therapy. The procedures were 
performed once a day, 5 days a week for the period of 
1 month. The wound healing process measured by 
digital planimetry was evaluated before physical 
procedures, immediately after the end of treatment, 
and 1, 3 months later as a follow-up. The results were 
relatively surprising, as only irradiations at the 
wavelength of 658 nm was found to be more effective 
than the other three methods and led to rapid and 
fairly spectacular therapeutic progress in comparison 
to the control group. Interestingly, the other 
wavelength of radiation (940 and 808 nm, much more 
popular in clinical practice than 658 nm), did not 
significantly influence the healing process and did not 
even show any statistically significant advantage over 
sham therapy. 
The above study results have confirmed the need 
to conduct a study with the aim to evaluate the 
mechanisms of healing with laser irradiation in the 
treatment of pressure ulcers. It seems that the lack of 
knowledge of the effects of laser therapy on healing 
processes at the molecular and immunological level 
(such as the expression of angio- and fibrogenic 
factors, and cytokine concentrations) significantly 
hinders the use of this method in clinical practice. 
Without establishing and understanding the effects of 
radiation on the wound and healing processes based 
on basic sciences, it is difficult to substantiate the use 
of laser irradiation technology in hospital or 
outpatient settings in patients with pressure ulcers. 
The aim of the present study was to evaluate the 
effect of laser irradiation at different wavelengths 940, 
808 and 658 nm (in reference to previous clinical trials 
of our team and the publication from 2013, and above 
all to conduct the same concept and methodology) on 
the expression of selected growth factors and 
inflammatory mediators at particular stages of the 
wound healing process. 
Materials and Methods  
Study Design 
 The study was performed between April 2015 
and October 2017 in two medical centers in 
accordance with the guidelines of the Declaration of 
Helsinki and the Principles for Good Clinical Practice, 
as well as respecting the rights and dignity of the 
other person. The study was approved by the local 
Bioethics Committee (file reference number 4/2014). 
Written informed consent was obtained from all 
patients. In addition, the study was registered 
prospectively on the Australian New Zealand Clinical 
Trial Registry platform (ACTRN12615000366550). 
This paper has been prepared using the CONSORT 
2010 guide for the reporting of parallel group 
randomized trials (Figure 1), as well as the associated 
documents for randomized trials of non-pharmacolo-
gical treatments [14]. 
Settings and Participants 
The study included patients diagnosed with a 
chronic wound of pressure ulcer-related etiology. The 
inclusion criteria were: (1) stage II, III or IV according 
to the EPUAP/NPUAP classification system for 
pressure ulcer [12], (2) wound area at least 0.5 cm2 and 
not more than 50 cm2, (3) duration of the condition 
between min. 6 to max. 24 months and (4) location of 
pressure ulcers in the sacrum and pelvis (Figure 2). 
The exclusion criteria were: (1) a clinically detectable 
wound infection (critical bacterial colonization 




confirmed by wound swab and bacteriological 
examination, foul odor, increased pain and 
inflammation in the tissue around the ulcer, 
lympho-flow and significant serous effusion), (2) use 
of drugs, such as corticosteroids, anticoagulants, 
opiates, antibiotics (3) use of special active dressings 
such as hydrocolloids, hydrogels, alginate, with the 
addition of metallic silver or any other type of 
therapeutic procedures different from those planned 
and used in this study, (4) non-compliance with ulcer 
management recommendations, (5) pregnancy, (6) 
ankle-brachial pressure index (ABPI) < 0.8, (7) 
diabetes (HbA1C > 7%), (8) systemic sclerosis, 
collagenases, psoriasis and other autoimmune 
diseases, (9) neoplastic disease, (10) allergic reactions 
(11) diagnosed mental illness, alcoholism or other 
addictions.  
 
Figure 2. Ulcer in sacrum area 
 
Figure 1. The CONSORT flow chart 
 




All patients had a stabilized and unified diet one 
month before the start of the study and their 
nutritional status was monitored using the 
Nutritional Risk Screening Tool (NRS 2002) [15]. 
Nutritional supplementation was used when 
necessary to ensure that the patients received the 
recommended quantity of proteins, vitamins, and 
minerals. To determine whether patients met the 
criteria described in the protocol and whether there 
has been a deterioration of health status (some 
exclusion criteria could appear during the study), 
they underwent tests including standard blood 
morphology with smear, immunoassays, HbA1c, 
cholesterol level, hepatic enzymes, urinalysis and 
renal hemodynamics, ECG) twice within three 
months before the experiment, and once during the 
study time. Blood samples were tested to screen 
patients for nutritional status markers and metabolic 
disorders, such as different types of anemia, thyroid 
dysfunction, impaired glycemic control, dehydration, 
protein deficit, and hypoalbuminemia. In this way, a 
homogeneous and representative population was 
ensured in the comparison groups. The flow of 
patients in the study at its subsequent stages is shown 
in Figure 1 and the analysis was performed on 67 
patients in total.  
Randomization and Blinding 
Patients were randomly allocated to four groups 
with the use of sealed envelopes with special codes 
inside. An administration official who had no further 
contact with the patient during the treatment and did 
not know the therapeutic details drew the envelopes. 
The devices were coded only with symbols, all the 
treatment parameters were prepared before the start 
of the study and the settings were fixed, thus the 
therapists performing laser therapy did not know 
anything about the doses of irradiation. Periodic 
monitoring of the apparatus was conducted by 
technicians who were not involved in the study and 
after treatment hours. Patients did not receive any 
information about group allocation and they could 
not distinguish the type of therapy. The collection of 
blood and wound tissue samples from the wound was 
done by other personnel who carried coded material 
for further diagnostics and the laboratory workers 
were unaware of any study details. The results for 
statistical analysis were also coded. Only the project 
coordinator and co-workers were able to decode the 
data, however, these employees did not have any 
contact with patients and could not influence the final 
results of the study. 
Interventions 
Patients from all groups received a basic 
treatment, including repositioning and mobilization, 
air pressure mattress and bed support surfaces, 
wound cleansing (0.9% normal saline). Additionally, 
skin in the wound area was cleaned with solutions: 1. 
(2-Propanolum 45%; 1-Propanolum 10%; 2-Biphenylol 
0.2%; hydrogen peroxide; purified water) and 2. 
(ethanol 46%; isopropyl alcohol 27%; benzyl alcohol 
1%; hydrogen peroxide; purified water). Patients 
received also the compound topical cream on the 
ulcer area (1 g contains 20 mg allantoin and 50 mg 
dexopanthenol as a 50% solution of panthenol in 
propylene glycol) with an outer layer of a wet 
dressing held in place by a medical-quality 
rubberized fabric. A dressing change was carried out 
1–2 times a day, depending on local exudation.  
Patients from all groups received laser therapy 
once a day, 5 times a week for 1 month. The EzLase 
940 (Biolase Technology, USA) and Rainbow Drops 
with SIX Laser 658 TS probe (Cosmogamma Group, 
Indonesia) devices were used for the treatments. 
There are semiconductor lasers (GaAlAs) which 
emitted a continuous radiation emission at separate 
wavelengths of 940 nm (group A), 808 nm (group B) 
and 658 nm (group C). The size of the laser spot was 
0.1 cm2 when scanning the ulcer surface with a 
cone-shaped applicator (compound movement with a 
frequency of 20 Hz along the ordinate axis and 0.5 Hz 
along the abscissa axis). The applicator was applied 
non-contact from a distance of 2 cm to the wound. The 
duration of a single protocol depended on the size of 
the wound, and the therapy was adjusted to obtain an 
average dose of 4 J/cm2 (direct dose measured on the 
surface of the wound using the Mentor MA10 device, 
ITAM Inc., Poland). In group D (sham therapy), laser 
therapy was applied in the same manner, but the 
device was off during each session (only the 
applicator was switched on to scan pressure ulcers 
using none coherent red visible light). 
Measures 
A fasting venous blood sample from the upper 
limb (5 ml) was collected three times – in the morning 
on the day prior to the treatment (day zero), after 2 
weeks of irradiation and the day after the monthly 
laser therapy. Blood serum was obtained in a 
standard manner by centrifugation. 
In addition, tissue samples measuring 3 x 3 x 3 
mm were taken from the bottom of the wound from 
all patients at the same three timepoints, i.e. on day 
zero, after 14 days and finally after the completed 
therapy- 4 weeks later). 
The collected tissue samples were immediately 
washed with cold 1X phosphate-buffered saline (PBS), 
then placed on ice and cut into smaller pieces and 
frozen immediately in liquid nitrogen and stored on 
ice for rapid homogenization. Samples for further 




testing were stored at -80° C. Samples were placed in 
a test tube with a cold radioimmunoprecipitation 
assay buffer (RIPA) – 600 μl of buffer for 10 mg of 
tissue – with dithiothreitol protease inhibitors (DTT, 
leupeptin and aprotinin). Homogenization and cell 
lysis were performed with the UP200St ultrasonic 
homogenizer (Hielscher-ultrasound technology, 
Germany) for 5 min in a cycle of 15 seconds of 
sonification and 10 seconds of rest at 180 W (keeping 
the tube on ice). After the homogenization process, 
the lysate was centrifuged for 20 min at 27,000 g. The 
collected supernatant was prepared for further 
testing. 
A quantitative sandwich ELISA enzyme-linked 
immunosorbent assay was used to determine the level 
of IL-6, IL-2 interleukins and TNF-α tumor necrosis 
factor and TGFβ1, VEGF growth factors in the serum 
and lysate of the collected tissues. The test was 
performed with the use of Hangzhou MultiSciences 
kits (China) and (R & D Systems, USA) according to 
the manufacturers' protocols. Standard solutions (100 
μl two-fold dilution), test samples diluted in buffer 
(20/80 μl) and biotin-bound specific detection 
antibodies (1: 100, 50 μl) were added to wells of 
microplates coated with specific monoclonal 
antibodies. Binding of the present antigens by 
immobilized antibodies occurred during incubation (2 
h at room temperature on a microplate shaker, 300 
rpm). After rinsing with buffer, streptavidin- 
horseradish peroxidase (HRP) solution (100 μl) was 
added to each well and incubated 45 min at room 
temperature on a microplate shaker. The color of the 
samples was obtained by adding tetramethylbenzi-
dine (TMB) solution and incubating in the dark at 
room temperature for 10 min. After obtaining the 
color, the reaction was terminated by washing with 
buffer. Optical density (OD) was measured in a 
microplate reader at wavelength of 450 nm. 
Statistical Analysis 
Statistica 12 (StatSoft, Inc., USA) was used to 
perform statistical analysis. All the studied 
quantitative variables were compared with the use of 
the Shapiro-Wilk test to determine the type of 
distribution. The comparisons between groups were 
performed using the non-parametric Kruskal-Wallis 
ANOVA test with multiple comparisons. The 
Friedman ANOVA test with multiple comparisons 
was used to compare results within the groups. The 
level of p ≤ 0.05 was considered statistically 
significant. In calculating our sample size we have 
allowed for: 
- up to 30% loss of participants (exclusion 
criteria); 
- the minimum statistically significant difference 
would be set at 15% of the baseline 
According to type I error, probability a = 0.05 
and test power 1-beta = 0.90 the detection of 
differences between four groups required at least 15 
patients in each group (total of 60 patients). 
Results 
Participant demographics 
Eighty-six patients were assessed for eligibility, 
of which sixteen patients were excluded from the 
study due to not meeting the criteria for inclusion. 
Seventy patients were randomized and allocated to 
the one of the intervention arms, however, two of 
them did not receive allocated intervention and one 
was excluded from analyses. Finally, sixty-seven 
patients were recruited, treated, and analyzed (group 
A – 940 nm: 17 patients; group B – 808 nm: 18 patients; 
group C – 658 nm: 16 patients; group D – sham 
therapy: 17 patients). The flow chart for study 
selection is shown in Figure 1 and the demographic 
and clinical characteristics are shown in Table 1. 
 
Table 1. Baseline demographic characteristics of patients in 
groups. 








Gender [n (%)]     
Female 12 (66.66) 11 (61.11) 11 (64.70) 11 (64.70) 
Male 6 (33.33) 7 (38.89) 6 (35.30) 6 (35.30) 
Age [years]     







BMI [n (%)]     
BMI > 30 1 (5.55) 1 (5.55) 1 (5.88) 1 (5.88) 
BMI < 19 1 (5.55) 1 (5.55) 1 (5.88) 1 (5.88) 
Disability in changing the 
position [n (%)] 
10 (55.55) 9 (50.00) 10 (58.82) 9 (52.94) 
Additional diseases [n (%)]     
General atherosclerosis 12 (66.66) 11 (61.11) 11 (64.70) 10 (58.82) 
Diabetes (HbA1C < 7%) 7 (38.88) 6 (33.33) 7 (41.17) 6 (35.30) 
Cerebral strokes 5 (27.77) 6 (33.33) 5 (29.41) 4 (23.52) 
Myocardial infarction history 5 (27.77) 5 (27.77) 5 (29.41) 4 (23.52) 
Multiple ulcers [n (%)] 5 (27.77) 4 (22.22) 4 (23.52) 5 (29.41) 
Wound area [cm2]     







Duration of ulcers [months]     







EPUAP/NPUAP scale [n (%)]     
II° 5 (27.77) 6 (33.33) 6 (35.30) 5 (29.41) 
III° 10 (55.55) 9 (50.00) 8 (47.05) 10 (58.82) 
IV° 3 (16.67) 3 (16.67) 3 (17.65) 2 (11.77) 
Ulcer placement [n (%)]     
Sacrum bone 12 (66.66) 11 (61.11) 10 (58.82) 9 (52.94) 
Ischial tuberosity 3 (16.67) 4 (22.22) 4 (23.52) 5 (29.41) 
Trochanter major 3 (16.67) 3 (16.67) 3 (17.65) 3 (17.65) 
 
Serum 
Immediately, the same day after the treatment it 
was clearly observed there was the greatest reduction 




in the concentration of pro-inflammatory interleukins 
in the blood in group C (658 nm). The significant 
change in these pro-inflammatory mediator levels 
[interleukin 2 (IL-2) with p=0.008 and interleukin 6 
(IL-6) with p=0.016] was noticed after two weeks of 
laser therapy. In the other groups, the inflammation 
was also reduced, but the process was not as marked 
as in group C. Similarly, in the case of tumor necrosis 
factor (TNF-α) concentration, where after two weeks 
of treatment with irradiation at a wavelength of 658 
nm, a rapid suppression was observed (p=0.001), 
whereas in the other groups, these results were much 
slower and not as obvious. Further, the analysis 
shows that there were no differences between groups 
A (940 nm), B (808 nm) and D (sham therapy), which 
indicates that laser therapy at these wavelengths does 
not bring an effective anti-inflammatory effect. 
However, the results in group C (658 nm) were 
significantly better than those obtained in the others 
groups. Detailed results are presented in Tables 2-4. 
 
Table 2. Serum levels of IL-2 before, in the middle and after 
treatment in the four groups (pg/ml). 
Group  Before 
[average (SD)] 
 2 wks [average 
(SD)] 
 After [average 
(SD)] 
 * p-value  
940 nm  95.45 (13.23)  74.34 (10.67)  66.78 (9.23)  0.034  
808 nm  100.21 (14.54)  69.47 (10.02)  67.78 (9.01)  0.032 
658 nm  97.89 (13.42)  35.66 (4.38)  26.45 (4.78)  0.008 
Sham therapy  94.11 (11.98)  70.21 (9.89)  66.36 (8.89)  0.035 
**p-value  p=0.351  0.012  0.012   
*Friedman ANOVA, level of significance (before vs. 2 wks vs. after) 
**Kruskal-Wallis ANOVA, level of significance (A vs. B vs. C vs. D group) 
 
Table 3. Serum levels of IL-6 before, in the middle and after 
treatment in the four groups (pg/ml). 
Group  Before 
[average (SD)] 
 2 wks [average 
(SD)] 
 After [average 
(SD)] 
 * p-value  
940 nm  32.12 (3.56)  24.11 (2.99)  22.46 (2.18)  0.042  
808 nm  33.10 (3.59)  24.79 (3.12)  23.02 (3.02)  0.042 
658 nm  32.55 (3.43)  14.18 (1.78)  11.37 (1.66)  0.016 
Sham therapy  31.98 (2.89)  24.44 (3.21)  22.69 (3.11)  0.042 
**p-value  p=0.411  0.028  0.026   
*Friedman ANOVA, level of significance (before vs. 2 wks vs. after) 
**Kruskal-Wallis ANOVA, level of significance (A vs. B vs. C vs. D group) 
 
Table 4. Serum levels of TNF-α before, in the middle and after 
treatment in the four groups (ng/ml). 
Group  Before 
[average (SD)] 
 2 wks [average 
(SD)] 
 After [average 
(SD)] 
 * p-value  
940 nm  228.33 (24.18)  131.33 (22.99)  123.77 (22.78)  0.026  
808 nm  230.02 (24.59)  128.09 (23.12)  122.32 (23.23)  0.024 
658 nm  227.89 (3.43)  75.03 (16.78)  63.08 (15.66)  0.001 
Sham therapy  227.35 (2.89)  126.67 (23.21)  121.92 (23.19)  0.024 
**p-value  p=0.468  0.018  0.021   
*Friedman ANOVA, level of significance (before vs. 2 wks vs. after) 
**Kruskal-Wallis ANOVA, level of significance (A vs. B vs. C vs. D group) 
 
Wound Tissue 
The positive changes in the measured serum 
parameters were associated with tumor necrosis 
factor activity within the wound area. Table 5 
illustrates the TNF-α levels. In all comparison groups, 
a significant decrease in the concentration of this 
inflammatory mediator was observed (p=0.033 for 904 
nm; p=0.033 for 808 nm; p=0.025 for 658 nm; and 
p=0.033 for sham therapy). Interestingly, again in the 
case of group C (658 nm), the change in TNF-α 
concentration was most intensive (≈75% reduction), 
whereas the changes in other groups were not as 
obvious (≈50% reduction). 
 
Table 5. Wound levels of TNF-α before, in the middle and after 
treatment in the four groups (pg/mg). 
Group  Before 
[average (SD)] 
 2 wks [average 
(SD)] 
 After [average 
(SD)] 
 * p-value  
940 nm  890.21 (657.33)  512.44 (463.21)  479.11 (389.99)  0.033  
808 nm  901.12 (743.19)  548.31 (476.10)  465.01 (379.22)  0.033 
658 nm  893.67 (687.09)  202.39 (169.12)  187.88 (125.44)  0.025 
Sham therapy  889.44 (685.17)  549.88 (478.36)  480.16 (333.89)  0.033 
**p-value  p=0.450  0.031  0.029   
*Friedman ANOVA, level of significance (before vs. 2 wks vs. after) 
**Kruskal-Wallis ANOVA, level of significance (A vs. B vs. C vs. D group) 
 
After irradiation (658 nm), the VEGF expression 
increased significantly within the first two weeks, and 
then it decreased and maintained a stable level (Table 
6). In contrast, the TGFβ1 activity remained level, but 
always higher in comparison to other groups (Table 
7).  
 
Table 6. Wound levels of VEGF before, in the middle and after 
treatment in the four groups (pg/mg). 
Group  Before 
[average (SD)] 
 2 wks [average 
(SD)] 
 After [average 
(SD)] 
 * p-value  
940 nm  302.35 (212.54)   371.40 (300.73)  311.21 (303.56)  0.044  
808 nm  299.03 (208.38)  367.21 (301.89)  300.76 (301.62)  0.043 
658 nm  289.27 (199.59)  476.22 (413.02)  357.09 (304.19)  0.030 
Sham therapy  300.67 (208.89)  368.08 (289.19)  299.82 (334.63)  0.044 
**p-value  p=0.480  0.038  0.046   
*Friedman ANOVA, level of significance (before vs. 2 wks vs. after) 
**Kruskal-Wallis ANOVA, level of significance (A vs. B vs. C vs. D group) 
 
Table 7. Wound levels of TGFβ1 before, in the middle and after 
treatment in the four groups (pg/mg). 
Group  Before 
[average (SD)] 
 2 wks [average 
(SD)] 
 After [average 
(SD)] 
 * p-value  
940 nm  121.15 (87.21)  138.27 (110.86)  129.39 (112.21)  0.202  
808 nm  125.04 (76.11)  142.07 (123.01)  137.10 (121.89)  0.215 
658 nm  123.22 (80.02)  312.54 (228.35)  306.21 (231.03)  0.023 
Sham therapy  117.72 (91.21)  130.88 (121.20)  131.02 (131.01)  0.219 
**p-value  p=0.329  0.012  0.012   
*Friedman ANOVA, level of significance (before vs. 2 wks vs. after) 
**Kruskal-Wallis ANOVA, level of significance (A vs. B vs. C vs. D group) 
 
Discussion 
The use of laser therapy in the treatment of 
hard-to-heal pressure ulcers still stimulates a lot of 
controversy. On the one hand, it is a simple and 
popular tool in everyday clinical practice, on the other 
hand, it the level of scientific evidence is extremely 




poor. Referring to the latest systematic review 
published in 2017 [9] on the use of laser therapy in 
patients with pressure ulcers, it can be clearly seen 
that there is a lack of reliable and well-done studies in 
this area. Machado et al. in their critical review of the 
literature found as many as 386 articles on this subject, 
but only four publications met the criteria for 
inclusion for further analysis. These four studies 
conclude that the greatest therapeutic effects are 
associated with radiation at a wavelength of 658 nm.  
This conclusion is in line with our own clinical 
experience and the results of the publication from 
2013 [13], however, a desire to understand the 
mechanisms in the process of healing pressure ulcers 
healing with the use of laser therapy contributed to 
the planning and conducting this research. With 
respect to the results we obtained, it seems that the 
successful effect of wound healing after irradiation at 
wavelengths of 658 nm is associated with an 
anti-inflammatory effect, as well as stimulation of 
such phenomena as angiogenesis, proliferation or 
remodeling of tissues during the process of wound 
closure. This is indirectly indicated by changes in the 
activity of the cytokines and growth factors examined 
in this study.  
The significant reduction in the concentration of 
interleukins in the blood in group C (658 nm) shows 
strong anti-inflammatory effect of laser radiation at a 
wavelength of 658 nm on the systemic level. 
Additionally, the rapid suppression of serum TNF-α 
level probably allows for a smooth transition from the 
inflammatory phase to wound proliferation. The 
positive changes of TNF-α activity in wound biopsies 
seem to reflect the elimination of the inflammatory 
reaction after two weeks of 658 nm irradiations and 
then stimulation of healing processes in the period of 
proliferation and remodeling of pressure ulcers. 
Besides, the VEGF expression increased significantly 
in group C within the first two weeks, which may be 
in our opinion an indicator of stimulation of 
angiogenesis, and then it decreased and maintained a 
stable level. The obtained results clearly show that the 
process of angiogenesis observed as changes in 
vascular endothelial growth factor activity (VEGF) 
and proliferation as changes in transforming growth 
factor beta 1 (TGFβ1) activity in wounds was the most 
intensive with radiation of 658 nm. Interestingly, 
electromagnetic radiation at a slightly different 
wavelength, for example, 940 or 808 nm, proved to be 
completely ineffective in stimulating these reactions 
in the wound, which also explains the poor clinical 
results and the lack of fast healing process of pressure 
ulcers when using these parameters. 
Up until now there is no similar study in the 
field of pressure ulcer treatment in the literature, 
hence it is difficult to compare our results with other 
scientific reports. This study is the first such trial, 
which certainly adds to its unique innovativeness. To 
our knowledge, only one article on laser therapy of 
chronic wounds, but of a different etiology can be 
found in the literature [14]. 
Ruh et al [16] in the latest report from 2018, 
described the laser treatment applied for twelve days 
(one treatment per day) using a similar wavelength to 
ours (660 nm) on diabetic-grade III and IV wounds. 
Unfortunately, the study included only eight patients 
without a control or comparison group. The 
researchers used a dose of 2 J / cm2 (in our study it 
was 4 J / cm2). Wound samples were collected twice, 
before the start of irradiation and after a 12-day series 
of treatments. They also evaluated the activity of the 
pro-inflammatory mediator TNF-α and growth 
factors VEGF and TGFβ1. It was observed that the 
TNF-α level decreased and the observed growth 
factors increased their activity. These results 
completely coincide with our findings, but since the 
Brazilian researchers only performed the treatment 
for 12 days, (in our case, the treatment lasted a 
month), it is not known whether further 
measurements in subsequent healing phases would 
be consistent with ours. 
Finally, it seems that the therapeutic basis in the 
effective healing of pressure ulcers is connected with 
laser irradiation at a wavelength of 658 nm and its 
influence on the inhibition of inflammatory processes 
in the wound and stimulation of angiogenesis and 
fibroblast proliferation. Laser therapy at wavelengths 
of 940 and 808 nm does not significantly affect the 
above-mentioned repair processes, which explains its 
low effectiveness in the treatment of pressure ulcers 
and contributes to the confusion when determining 
the effectiveness of laser therapy. 
Limitations of the Study 
Our study is a pilot report and we are continuing 
to enroll eligible patients to increase the number of 
patients. Notwithstanding this limitation, relate back 
to original study results and what this study has 
added. In further studies we should collect blood 
samples (for nutritional status markers) also before 
and after the experimental procedure and monitor 
hypoalbuminemia status especially. It is also 
recognized that only a few factors related to healing 
and inflammation have been analyzed. It is necessary 
to determine the involvement of other important 
factors in the treatment of pressure ulcers, for 
example, PDGF, FGF or EGF growth factors, as well 
as the extremely interesting activities of MMP-2 and 
MMP-9 metalloproteinases with respect to the tissue 
TIMP inhibitor; and COX-2 activity. It would be also 




helpful to analyze the NGF as an additional marker 
considering its angiogenesis stimulation by activating 
multiple pathways [17, 18]. Besides, in further studies 
we would like consider to quantify the effects of laser 
therapy directly on tissue samples. Measuring on 
tissue homogenates the levels of GFs as well as of 
interleukins could reduce the bias associated to 
systemic diseases and associated, but not discovered, 
comorbidities. The limitation of our study is lack of 
follow up assessment too. 
Conclusions 
In the present study, we showed that the 
effective healing of pressure ulcers is connected with 
laser irradiation at a wavelength of 658 nm. We 
believe that this effect is related to the inhibition of 
inflammatory processes in the wound and stimulation 
of angiogenesis and fibroblast proliferation at this 
specific radiation (based both on concentration of 
interleukins and TNF-α serum level and VEGF, 
TGFβ1, TNF-α activities in wound biopsies). Laser 
therapy at wavelengths of 940 and 808 nm does not 
significantly affect the above-mentioned repair 
processes, which explains its low effectiveness in the 
treatment of pressure ulcers. 
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